Resolution of Cullen’s sign in patient with metastatic melanoma responding to hypoxia-activated prodrug TH-302
Submitted: 27 October 2011
Accepted: 31 October 2011
Published: 1 December 2011
Accepted: 31 October 2011
Abstract Views: 1756
PDF: 664
HTML: 671
HTML: 671
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Supporting Agencies
Threshold PharmaceuticalsWeiss, G. J., Lewandowski, K., Oneall, J., & Kroll, S. (2011). Resolution of Cullen’s sign in patient with metastatic melanoma responding to hypoxia-activated prodrug TH-302. Dermatology Reports, 3(3), e56. https://doi.org/10.4081/dr.2011.e56
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.